Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
暂无分享,去创建一个
Olga V. Demler | O. Demler | A. Khera | P. Ridker | R. Glynn | D. Rader | S. Mora | S. Adelman | H. Collins
[1] P. Ridker,et al. Circulating N‐Linked Glycoprotein Side‐Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial , 2016, Journal of the American Heart Association.
[2] A. Lerman,et al. Patients With Coronary Endothelial Dysfunction Have Impaired Cholesterol Efflux Capacity and Reduced HDL Particle Concentration. , 2016, Circulation research.
[3] T. Vaisar,et al. Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity[S] , 2015, Journal of Lipid Research.
[4] D. Rader,et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study , 2015, The lancet. Diabetes & endocrinology.
[5] A. Khera,et al. Relation of Black Race between High Density Lipoprotein Cholesterol Content, High Density Lipoprotein Particles and Coronary Events (From the Dallas Heart Study) , 2015, The American journal of cardiology.
[6] T. Weichhart,et al. HDL cholesterol efflux capacity and cardiovascular events. , 2015, The New England journal of medicine.
[7] A. Khera,et al. HDL cholesterol efflux capacity and incident cardiovascular events. , 2014, The New England journal of medicine.
[8] Sarah Parish,et al. Effects of extended-release niacin with laropiprant in high-risk patients. , 2014, The New England journal of medicine.
[9] Jennifer G. Robinson,et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.
[10] Jennifer G. Robinson,et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.
[11] S. Hazen,et al. Effects of Native and Myeloperoxidase-Modified Apolipoprotein A-I on Reverse Cholesterol Transport and Atherosclerosis in Mice , 2014, Arteriosclerosis, thrombosis, and vascular biology.
[12] N. Paynter,et al. High-Density Lipoprotein Particle Subclass Heterogeneity and Incident Coronary Heart Disease , 2014, Circulation. Cardiovascular quality and outcomes.
[13] A. Khera,et al. Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention An Intervention Trial Evaluating Rosuvastatin) , 2013, Circulation.
[14] Amy S. Shah,et al. Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond1 , 2013, Journal of Lipid Research.
[15] P. Ridker,et al. High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy , 2013, Circulation.
[16] S. Hazen,et al. Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular Risks , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[17] D. DeMets,et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[18] Markus Abt,et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.
[19] Samia Mora,et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). , 2012, Journal of the American College of Cardiology.
[20] R. Collins,et al. Lipids and Lipoproteins and Risk of Different Vascular Events in the MRC/BHF Heart Protection Study , 2012, Circulation.
[21] P. Ridker,et al. Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial. , 2012, Clinical chemistry.
[22] P. Ridker,et al. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). , 2012, Journal of the American College of Cardiology.
[23] S. Pennathur,et al. Myeloperoxidase Targets Apolipoprotein A-I, the Major High Density Lipoprotein Protein, for Site-Specific Oxidation in Human Atherosclerotic Lesions* , 2012, The Journal of Biological Chemistry.
[24] P. Toth. On-Treatment Non–High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy: JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) , 2012 .
[25] William Weintraub,et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.
[26] Robert L Wilensky,et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.
[27] P. Toth. Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis , 2011 .
[28] Børge G Nordestgaard,et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial , 2009, The Lancet.
[29] Samia Mora,et al. Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women , 2009, Circulation.
[30] N. Wareham,et al. High-Density Lipoprotein Particle Size and Concentration and Coronary Risk , 2009, Annals of Internal Medicine.
[31] P. Libby,et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.
[32] A. Tall,et al. Cholesterol efflux pathways and other potential mechanisms involved in the athero‐protective effect of high density lipoproteins , 2008, Journal of internal medicine.
[33] L. Kuller,et al. Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. , 2007, Atherosclerosis.
[34] H. Bloomfield,et al. Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial , 2006, Circulation.